Navigating the Maze
Treatment-Resistant Depression: What It Is and What Comes Next
Treatment-Resistant Depression (TRD) is not a diagnosis of failure; it is a recognized clinical category. It is typically defined as a lack of response to at least two adequate trials of antidepressants from different classes. Having TRD does not mean a person is “untreatable.” It simply means that the first-line, standard approach hasn’t worked, and it’s time to escalate to more advanced, specialized strategies.
Once a patient enters the realm of TRD, the thinking shifts from “which SSRI?” to a broader, more aggressive strategy.
Step 1: Optimize and Re-evaluate
Before labeling a patient as “treatment-resistant,” a clinician must ensure the previous trials were truly “adequate.” Was the dose high enough? Was it taken for a long enough duration (at least 6-8 weeks)? Was adherence a factor? Often, what appears to be resistance is simply a suboptimal trial.
Step 2: Switch to a Different Class
If a patient has failed two SSRIs, staying within the SSRI class is unlikely to yield a different result. The next step is usually a switch to a different mechanism: an SNRI (like venlafaxine), an NDRI (bupropion), or an atypical agent (like mirtazapine). Some psychiatrists will also consider a combination of these, such as the “California Rocket Fuel”—a combination of venlafaxine and mirtazapine—which targets multiple neurotransmitter systems simultaneously.
Step 3: Augmentation
As discussed, this involves adding a non-antidepressant medication. Aripiprazole (Abilify) is the only medication with an FDA indication for adjunctive treatment in TRD. Lithium is another powerful, evidence-based augmenting agent.
Step 4: Revisiting Older Agents
If modern agents fail, clinicians will often turn to the older, more potent classes: Tricyclic Antidepressants (TCAs) or Monoamine Oxidase Inhibitors (MAOIs). These drugs are highly effective but require careful monitoring for side effects, dietary restrictions (for MAOIs), and cardiac safety.
Step 5: Neurostimulation
When medications repeatedly fail, it’s time to consider interventions that directly modulate brain activity. These are not “shock therapy” of the past; they are precise, modern procedures.
Transcranial Magnetic Stimulation (TMS): A non-invasive procedure that uses magnetic fields to stimulate nerve cells in the dorsolateral prefrontal cortex, an area underactive in depression. It’s done in an office setting, no anesthesia required, and has a strong track record for TRD.
Electroconvulsive Therapy (ECT): The gold standard for severe, life-threatening, or catatonic depression. Under general anesthesia, a controlled seizure is induced, leading to widespread neurochemical and neuroplastic changes. Despite its stigma, it is the most effective treatment for severe TRD, with response rates above 70-80%.
The journey through TRD is arduous, but the existence of multiple steps—from optimizing doses to neurostimulation—means that there are always more doors to open. The key is to have a psychiatrist experienced in these advanced strategies guiding the way.